Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like B*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000097	Bausch Health US, LLC	04/22/2025	00187581030	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct	01/01/2025	200.26	2223.10	06/27/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187581130	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct	01/01/2025	263.99	2930.60	06/27/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187581230	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct	01/01/2025	600.77	6669.18	06/27/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187006410	ATIVAN® Tablets 1mg 1,000s	01/01/2025	3584.97	48397.06	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187006301	ATIVAN® Tablets .5mg 100s	01/01/2025	274.02	3699.21	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187006401	ATIVAN® Tablets 1mg 100s	01/01/2025	366.05	4941.61	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187006501	ATIVAN® Tablets 2mg 100s	01/01/2025	583.36	7875.36	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187301220	MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle	01/01/2025	114.89	1756.26	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187301030	MESTINON 60mg TABLETS 100s (pyridostigmine bromide)	01/01/2025	141.46	2162.23	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187301330	MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT	01/01/2025	80.49	1230.33	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187000402	SILIQ™ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes)	01/01/2025	516.78	5736.81	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187073030	WELLBUTRIN® XL 150mg Tablets, 30ct	01/01/2025	197.72	2194.89	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187073090	WELLBUTRIN® XL 150mg Tablets, 90ct	01/01/2025	593.20	6585.07	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187073130	WELLBUTRIN® XL 300mg Tablets, 30ct	01/01/2025	261.00	2897.35	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000024	Bayer	01/06/2025	50419039501	Nubeqa 300 mg tab 120 count	01/01/2025	679.20	14253.60	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419017105	Stivarga 40 mg tab 21 count bottle	01/01/2025	229.32	5960.85	07/09/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419017101	Stivarga 40 mg tab 28 count bottle	01/01/2025	305.76	7947.80	06/02/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419017103	Stivarga 40 mg tab 3x28 count bottle	01/01/2025	917.28	23843.40	06/02/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419017106	Stivarga 40 mg tab 4x21 count bottle	01/01/2025	917.28	23843.40	07/09/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419039101	VITRAKVI 100MG CAPS BT 1x60	01/01/2025	1559.40	40544.40	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419039201	Vitrakvi 20 mg/mL oral solution	01/01/2025	693.00	18019.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419039001	VITRAKVI 25MG CAPS BT 1x60	01/01/2025	519.60	13514.40	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	01/27/2025	68418793906	Diacomit 250mg Capsule 60ct	01/27/2025	137.91	2108.05	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	01/27/2025	68418794106	Diacomit 250mg powder in packet 60ct	01/27/2025	137.91	2108.05	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	01/27/2025	68418794006	Diacomit 500mg Capsule 60ct	01/27/2025	275.82	4216.10	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	01/27/2025	68418794206	Diacomit 500mg powder in packet 60ct	01/27/2025	275.82	4216.10	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135081102	BRINEURA 150 mg/5 mL INJ, Kit (Two 5 mL vials (30mg/ml) (IEV)-one 5ml vial)	01/01/2025	1496.00	34754.00	05/05/2036	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135002001	NAGLAZYME 1MG/ML INJ, (5 mL vial)	01/01/2025	105.00	2451.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135075620	PALYNZIQ 10MG/0.5ML INJ,SYR,0.5MLsingle-dose prefilled syringe	01/01/2025	29.00	659.00	02/03/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135005890	PALYNZIQ 2.5MG/0.5ML INJ,SYR,0.5ML single-dose prefilled syringe	01/01/2025	29.00	659.00	02/03/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135067340	PALYNZIQ 20MG/ML INJ,SYR,1ML single-dose prefilled syringe	01/01/2025	29.00	659.00	02/03/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135067345	PALYNZIQ 20MG/ML INJ,SYR,1ML Ten 1 mL single- dose prefilled syringes	01/01/2025	290.00	6590.00	02/03/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135010001	VIMIZIM 1MG/ML INJ,SOLN,5ML vial	01/01/2025	64.00	1485.00	01/10/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135011966	VOXZOGO .56MG/VIAL, Ten .56mg vial	01/01/2025	463.00	10746.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135008236	VOXZOGO 0.4MG/VIAL, Ten .4mg vial	01/01/2025	463.00	10746.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135018193	VOXZOGO 1.2MG/VIAL, Ten 1.2mg vial	01/01/2025	463.00	10746.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000078	Bristol Myers Squibb	04/15/2025	59572051502	ABECMA®, 300 to 460 × 106 CAR Positive Viable T Cells in 250 mL Bag for Intravenous Infusion	01/01/2025	29904.48	528312.43	02/09/2036	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	419500.00	419500.00	2021	419500.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572051503	ABECMA®, 300 to 460 × 106 CAR Positive Viable T Cells in 500 mL Bag for Intravenous Infusion	01/01/2025	29904.48	528312.43	02/09/2036	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	419500.00	419500.00	2021	419500.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572051501	ABECMA®, 300 to 460 x 106 CAR Positive T Cells in 50 mL Bag for Intravenous Infusion	01/01/2025	29904.48	528312.43	02/09/2036	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	419500.00	419500.00	2021	419500.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73153090001	BREYANZI®, 50 to 110 × 106 CAR Positive Viable T Cells in Vials for Infusion	01/01/2025	43872.97	531350.40	08/20/2033	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	410310.00	410310.00	2021	410310.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73625011311	CAMZYOS®, 10 mg capsule / 30 Count Bottle	01/01/2025	368.65	8560.93	06/19/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/17/2020	Myokardia	13100000000	None	Bristol-Myers Squibb Company (BMS) acquired Myokardia in November 2020 for $13,100,000,000.	7356.16	7356.16	2022	7356.16	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73625011411	CAMZYOS®, 15 mg capsule / 30 Count Bottle	01/01/2025	368.65	8560.93	06/19/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/17/2020	Myokardia	13100000000	None	Bristol-Myers Squibb Company (BMS) acquired Myokardia in November 2020 for $13,100,000,000.	7356.16	7356.16	2022	7356.16	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73625011111	CAMZYOS®, 2.5 mg capsule / 30 Count Bottle	01/01/2025	368.65	8560.93	06/19/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/17/2020	Myokardia	13100000000	None	Bristol-Myers Squibb Company (BMS) acquired Myokardia in November 2020 for $13,100,000,000.	7356.16	7356.16	2022	7356.16	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73625011211	CAMZYOS®, 5 mg capsule / 30 Count Bottle	01/01/2025	368.65	8560.93	06/19/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/17/2020	Myokardia	13100000000	None	Bristol-Myers Squibb Company (BMS) acquired Myokardia in November 2020 for $13,100,000,000.	7356.16	7356.16	2022	7356.16	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572071030	IDHIFA®, 100MG tablet 30 count bottle	01/01/2025	2039.67	36034.17	09/16/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	25742.52	24872.00	2017	24872.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572070530	IDHIFA®, 50MG tablet 30 count bottle	01/01/2025	2039.67	36034.17	09/16/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	25742.52	24872.00	2017	24872.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572072012	INREBIC®, 100MG capsules 120 count bottle	01/01/2025	1188.50	27599.66	12/16/2026	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	21000.00	21000.00	2019	21000.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572073007	ONUREG®, 200MG tablets 7 count blister card	01/01/2025	381.96	13114.02	06/03/2030	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	10579.06	10579.06	2021	10579.06	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572074007	ONUREG®, 300MG tablets 7 count blister card	01/01/2025	381.96	13114.02	06/03/2030	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	10579.06	10579.06	2021	10579.06	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003218851	ORENCIA®, 125 mg/mL single-dose autoinjector, carton of 4	01/01/2025	256.29	5951.56	02/18/2028	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003218811	ORENCIA®, 125 mg/mL, single-dose prefilled syringe	01/01/2025	256.29	5951.56	02/18/2028	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003218713	ORENCIA®, 250 mg lyophilized powder	01/01/2025	51.19	1513.67	12/19/2026	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003281411	ORENCIA®, 50 mg/0.4mL, single dose prefilled syringe, 4 SYR	01/01/2025	256.29	5951.56	02/18/2028	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003281811	ORENCIA®, 87.5 mg/0.7 mL, single dose prefilled syringe, 4 SYR	01/01/2025	256.29	5951.56	02/18/2028	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050100	POMALYST®, 1MG capsules 100 count	01/01/2025	4915.45	114147.61	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050121	POMALYST®, 1MG capsules 21 count	01/01/2025	1032.24	23971.00	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050200	POMALYST®, 2MG capsules 100 count	01/01/2025	4915.45	114147.61	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050221	POMALYST®, 2MG capsules 21 count	01/01/2025	1032.24	23971.00	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050300	POMALYST®, 3MG capsules 100 count	01/01/2025	4915.45	114147.61	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050321	POMALYST®, 3MG capsules 21 count	01/01/2025	1032.24	23971.00	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050400	POMALYST®, 4MG capsules 100 count	01/01/2025	4915.45	114147.61	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050421	POMALYST®, 4MG capsules 21 count	01/01/2025	1032.24	23971.00	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572089028	ZEPOSIA®, 0.23,0.46,0.92MG 28CT KIT US	01/01/2025	373.37	8670.58	05/14/2029	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	7636.64	7636.64	2023	7636.64	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572081007	ZEPOSIA®, 0.23,0.46MG TITR STR PCK 7CT US (Wallet)	01/01/2025	93.34	2167.65	05/14/2029	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	1649.32	1649.32	2020	1649.32	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572082030	ZEPOSIA®, 0.92MG CAP 30CT BTL US	01/01/2025	400.04	9289.90	05/14/2029	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	7068.49	7068.49	2020	7068.49	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.